Rupee rises 17 paise to close at 89.88 against U.S. dollar
The Hindu
Rupee rises 17 paise to close at 89.88 against the U.S. dollar amid retreating dollar and crude oil prices.
Sensex drops 42 points after two-day rally as IT shares face profit-taking amidst mixed global market cues.
Cholamandalam Investment dismisses Cobrapost's misgovernance allegations as baseless, reaffirming commitment to compliance and transparency.
Gold and silver prices surge to record highs as investors seek safe havens amid geopolitical tensions and rate-cut expectations.
Stock markets decline after two days of gains, with subdued trading expected amid a holiday-shortened week.
Rupee dips to 89.73 against the dollar as Sensex and Nifty also decline amid FII outflows and weak market conditions.
Mercedes-Benz settles multistate emissions allegations for $149.6 million, addressing illegal devices in over 211,000 vehicles.
U.S. approves Wegovy pill for weight loss, expanding access to obesity treatment with a convenient daily oral option.
RBI Bulletin highlights resilient economic activity in India, driven by robust demand, despite challenges in external trade and inflation.
Biofabri and Bharat Biotech partner to advance MTBVAC, a tuberculosis vaccine, ensuring equitable access and manufacturing readiness in India.
India anticipates doubling trade with New Zealand to $5 billion in five years following a historic women-led free trade agreement.
Rupee dips 3 paise to 89.70 against the dollar amid trade deal concerns and rising crude oil prices.
Government to release new series of retail inflation, GDP data from February, IIP from May next year
The Indian government will release new macroeconomic data series, including GDP and inflation, starting February 2026.
Granules India secures U.S. FDA tentative approval for its ADHD generic, enhancing access to critical therapy and expanding its generics portfolio.